| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/16/1999 | CA2321834A1 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis |
| 09/16/1999 | CA2321832A1 Heterocyclyl anthracyclinone derivatives |
| 09/16/1999 | CA2321026A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 09/16/1999 | CA2288240A1 Methods and compositions for delivery of taxanes |
| 09/15/1999 | EP0941994A1 Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity |
| 09/15/1999 | EP0941341A1 Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy |
| 09/15/1999 | EP0941339A1 Therapeutic gene |
| 09/15/1999 | EP0941327A1 Human g-protein receptor hcegh45, a pacap-like (g-protein pituitary adenylate cyclase activating polypeptide-like) receptor |
| 09/15/1999 | EP0941326A1 Murine guanine nucleotide exchange factor (mngef) and human homologues thereof |
| 09/15/1999 | EP0941319A1 Peptides capable of inhibiting the endocytosis of the app and corresponding nucleotide sequences |
| 09/15/1999 | EP0941249A1 Novel histamine h2 receptor |
| 09/15/1999 | EP0941242A2 Secreted proteins and polynucleotides encoding them |
| 09/15/1999 | EP0941239A1 Vertebrate homologues of unc-53 protein of c. elegans |
| 09/15/1999 | EP0941225A1 Piperidine derivatives |
| 09/15/1999 | EP0941223A1 Certain pyrazole derivatives as corticotropin-releasing factor receptor crf1 specific ligands |
| 09/15/1999 | EP0941113A1 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors |
| 09/15/1999 | EP0941112A1 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors |
| 09/15/1999 | EP0941109A1 Pretreatment with growth factors to protect against cns damage |
| 09/15/1999 | EP0941108A1 Wound healing and treatment of fibrosis |
| 09/15/1999 | EP0941104A1 Peptide synthesis with sulfonyl protecting groups |
| 09/15/1999 | EP0941093A1 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| 09/15/1999 | EP0941092A1 Use of nk-1 receptor antagonists for treating major depressive disorders |
| 09/15/1999 | EP0941090A1 Pharmaceutical compositions containing n-sulphonyl indolin derivatives |
| 09/15/1999 | EP0941089A2 Compositions and methods for treating or preventing inflammatory diseases |
| 09/15/1999 | EP0804239B1 Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
| 09/15/1999 | EP0799188B1 Amides of mono and dicarboxylic acids with glycosamines, selectively active on the cannabinoid peripheral receptor |
| 09/15/1999 | EP0759899B1 Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| 09/15/1999 | EP0733051B1 Bicyclic heterocycles as neurokinin a antagonists |
| 09/15/1999 | EP0656001B1 Novel 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase |
| 09/15/1999 | EP0652752B1 Water-dispersible tablets |
| 09/15/1999 | EP0637242B1 Agents for treating substance abuse disorders |
| 09/15/1999 | CN1228779A Spirocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228778A Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists |
| 09/15/1999 | CN1228775A Benzofurans and benzopyrans as chronobiological agents |
| 09/15/1999 | CN1228697A Method for in vivo reduction of iron levels and compositions useful therefor |
| 09/15/1999 | CN1228695A Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta [b] benzofurans |
| 09/15/1999 | CN1228414A New benzocyclobutane compounds, process for their preparation and pharmaceutical compositions containing them |
| 09/15/1999 | CN1228332A Drug for curing migraine and its preparing method |
| 09/14/1999 | US5952499 Therapeutic compound-fatty acid conjugates |
| 09/14/1999 | US5952495 Preparation of 14-hydroxynormorphinones from normorphinones |
| 09/14/1999 | US5952483 Human IκB-β |
| 09/14/1999 | US5952481 DNA encoding ubiquitin conjugating enzymes |
| 09/14/1999 | US5952388 Administering effective dosage |
| 09/14/1999 | US5952383 Liquid support oil, suspending agent, homogenizing agent, surfactant and expedients; antiinflammatory agents |
| 09/14/1999 | US5952369 Pyrrolidinyl hydroxamic acid compounds and their production process |
| 09/14/1999 | US5952362 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonamides and ureas and their use |
| 09/14/1999 | US5952360 Admisnistering to a mammal certain phenyl oxazoles or phenyl thiazoles |
| 09/14/1999 | US5952346 Inhibits the actions of the alzheimer's protein amyloid (beta/a4) in isolated endothelial cells; quinoline derivatives |
| 09/14/1999 | US5952344 Treating and control of diseases which represent therapeutic indications for nmda(n-methyl-d-aspertate) receptor subtype specific blokers by administering tetrahydroisoquinoline derivatives |
| 09/14/1999 | US5952337 Remedy and preventive for nervous system disorders |
| 09/14/1999 | US5952325 Tricyclic spiro compounds process for their preparation and their use of 5HT1D receptor antagonists |
| 09/14/1999 | US5952322 Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| 09/14/1999 | US5952315 Treating physiological disorders, disorders of the central nervous system such as anxiety, depression and psychosis with an antidepressant |
| 09/14/1999 | US5952312 NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration |
| 09/14/1999 | US5952232 Expandible microparticle intracellular delivery system |
| 09/14/1999 | US5952214 Human growth-related CDC10 homolog |
| 09/14/1999 | US5952181 Hybridizing polynucleotide sequence to complementary polynucleotide forming a complex, detecting complex formation; anticarcinogenic agent, treatment of psychological disorders, alzheimer's disease |
| 09/14/1999 | US5952175 DNA encoding a human progesterone receptor complex p23-like protein |
| 09/14/1999 | CA2153264C New cyclopropyl derivatives, preparation method thereof and applications |
| 09/14/1999 | CA2150483C Pyrazoles and pyrazolopyrimidines |
| 09/14/1999 | CA2006356C Arylpiperazinylbutyl-dihydroindoles and related compounds |
| 09/11/1999 | CA2231968A1 Method of producing a nicotine medicament |
| 09/10/1999 | WO1999045115A1 Human synapse related glycoproteins (hsrp) |
| 09/10/1999 | WO1999045108A2 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines |
| 09/10/1999 | WO1999045024A1 Cholenic acid amides and pharmaceutical compositions thereof |
| 09/10/1999 | WO1999045011A1 Glycine transport inhibitors |
| 09/10/1999 | WO1999045009A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 09/10/1999 | WO1999045007A1 Crf antagonistic pyrazolo[4,3-b]pyridines |
| 09/10/1999 | WO1999045006A1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 09/10/1999 | WO1999044989A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | WO1999044623A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | WO1999044615A1 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism |
| 09/10/1999 | WO1999044613A1 Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v1a and v2 receptors |
| 09/10/1999 | WO1999044612A1 Substituted quinazolines and analogs and the use thereof |
| 09/10/1999 | WO1999044610A1 Combination of a selective nmda nr2b antagonist and an opioid analgesic |
| 09/10/1999 | WO1999044602A1 Inflammatory cell inhibitors |
| 09/10/1999 | WO1999044596A2 Glycine transport inhibitors |
| 09/10/1999 | WO1999044591A1 Extended release dosage form |
| 09/10/1999 | WO1999044581A2 Pharmaceutical composition of topiramate |
| 09/10/1999 | WO1999027949A9 METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE |
| 09/10/1999 | WO1999021617B1 Allosteric adenosine receptor modulators |
| 09/10/1999 | CA2322486A1 Inflammatory cell inhibitors |
| 09/10/1999 | CA2322442A1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 09/10/1999 | CA2322381A1 Human synapse related glycoproteins (hsrp) |
| 09/10/1999 | CA2322201A1 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism |
| 09/10/1999 | CA2322164A1 Glycine transport inhibitors |
| 09/10/1999 | CA2322136A1 Glycine transport inhibitors |
| 09/10/1999 | CA2321737A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | CA2321685A1 Combination of a selective nmda nr2b antagonist and an opioid analgesic |
| 09/10/1999 | CA2317502A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | CA2249661A1 Novel compounds |
| 09/10/1999 | CA2249041A1 Novel compounds |
| 09/08/1999 | EP0940391A2 Quinoline derivatives as tachykinin NK3 receptor antagonists |
| 09/08/1999 | EP0940386A1 Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them |
| 09/08/1999 | EP0940139A2 Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers |
| 09/08/1999 | EP0939821A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 09/08/1999 | EP0939751A1 Macrophage lipid chemoattractant |
| 09/08/1999 | EP0939659A1 Device for transdermal electrotransport delivery of fentanyl and sufentanil |
| 09/08/1999 | EP0939654A1 Association of no syntase inhibitors with trappers of oxygen reactive forms |
| 09/08/1999 | EP0939636A1 Application of thalidomide to the treatment of parkinson's disease and parkisonian syndromes |